Youre adding a drug to your cabinet.
Login or Signup to complete this action, or Cancel.
Schering-Plough posts $3.4B loss in 4Q on charges related to ... - PR-Inside.com (Pressemitteilung)
Key profit drivers for Schering-Plough include the arthritis treatment Remicade and the allergy treatment Nasonex. Quarterly Remicade sales rose 35 percent ...